EUVIMEDEUVIMED entdecken
Crossref

A Founder Allele in SGCG Combining Missense Variant and Multi‐Exon Duplication in Turkish Patients With Sarcoglycanopathy

Abdullah Sezer iD, Afife Büke, Hasan Hüseyin Kazan, Ahmet Kablan iD, Mustafa Tarık Alay iD, Beril Talim, Deniz Yüksel, Hanife Saat

Clinical Genetics · 2026

DOI: 10.1111/cge.70041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Genetics, 2026. Verfasst von Abdullah Sezer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Ankara Etlik City Hospital, Ankara, Türkiye. Hauptthemen laut MEDLINE: Sarcoglycans, Sarcoglycanopathies, Founder Effect, Mutation, Missense. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sarcoglycanopathies are autosomal recessive muscular dystrophies characterized by progressive muscle weakness and represent a major subset of limb‐girdle muscular dystrophies (LGMDs). They result from pathogenic variants in sarcoglycan genes ( SGCA , SGCB , SGCD , and SGCG ), which encode subunits of a tetrameric transmembrane complex that stabilizes the dystrophin‐associated glycoprotein complex. Among these, SGCG is commonly affected and is associated with LGMD2C/R5. Several founder variants in SGCG have been reported across different populations. Here, we describe a novel founder allele in the Turkish population, comprising a missense variant (c.392A>G, p.Lys131Arg) and a copy number gain (exon 1–4 duplication) that occurs in cis. Through an inductive screening strategy, we identified these linked variants in 11 individuals: five affected patients from four families and six unrelated incidental carriers. Haplotype analysis confirmed a shared genomic background supporting a founder effect. Affected individuals carried the allele in a homozygous or compound heterozygous state with other pathogenic SGCG variants. Molecular and histopathological investigations revealed that the duplicated allele results in mRNA decay and loss of SGCG protein expression. This study represents the first report of a disease‐associated duplication in SGCG, highlighting a novel founder allele composed of two linked variants that contribute to sarcoglycanopathy in a specific population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcoglycansSarcoglycanopathiesFounder EffectMutation, MissenseGene DuplicationHumansTurkeyFemaleMaleAllelesExonsPedigreeAdultChildAdolescentHaplotypes

Stichwörter der Autor:innen

SGCGduplicationfounder variantlimb‐girdle muscular dystrophysarcoglycanopathy

Substanzen

SarcoglycansSGCG protein, human

Autor:innen und Institutionen

  • Department of Medical Genetics, Ankara Etlik City Hospital, Ankara, Türkiye.
  • Department of Medical Biology, Gülhane Research and Training Hospital, Ankara, Türkiye.
  • Pediatric Pathology Unit, Department of Pediatrics, Hacettepe University, Ankara, Türkiye.
  • Department of Pediatric Neurology, Ankara Etlik City Hospital, Ankara, Türkiye.

ORCID-Profile: Abdullah Sezer, Ahmet Kablan, Mustafa Tarık Alay

Zitieren

APA

Sezer, A., Büke, A., Kazan, H. H., Kablan, A., Alay, M. T., Talim, B., Yüksel, D., & Saat, H. (2026). A Founder Allele in SGCG Combining Missense Variant and Multi‐Exon Duplication in Turkish Patients With Sarcoglycanopathy. Clinical Genetics. https://doi.org/10.1111/cge.70041

Vancouver

Sezer A, Büke A, Kazan HH, Kablan A, Alay MT, Talim B, et al. A Founder Allele in SGCG Combining Missense Variant and Multi‐Exon Duplication in Turkish Patients With Sarcoglycanopathy. Clinical Genetics. 2026. doi:10.1111/cge.70041

BibTeX
@article{Sezer2026,
  author = {Sezer, Abdullah and Büke, Afife and Kazan, Hasan Hüseyin and Kablan, Ahmet and Alay, Mustafa Tarık and Talim, Beril and Yüksel, Deniz and Saat, Hanife},
  title = {A Founder Allele in SGCG Combining Missense Variant and Multi‐Exon Duplication in Turkish Patients With Sarcoglycanopathy},
  journal = {Clinical Genetics},
  year = {2026},
  doi = {10.1111/cge.70041}
}
Kostenlos starten →